MARKET

BLUE

BLUE

Bluebird Bio Inc
NASDAQ
0.4660
+0.0020
+0.43%
After Hours: 0.4800 +0.014 +3.00% 19:57 11/01 EDT
OPEN
0.4660
PREV CLOSE
0.4640
HIGH
0.4862
LOW
0.4601
VOLUME
3.47M
TURNOVER
--
52 WEEK HIGH
5.53
52 WEEK LOW
0.4529
MARKET CAP
90.36M
P/E (TTM)
-0.2132
1D
5D
1M
3M
1Y
5Y
1D
bluebird bio Inc <BLUE.OQ> expected to post a loss of 36 cents a share - Earnings Preview
Reuters · 13h ago
Crispr Therapeutics: Avoid Catching The Falling Knife This Time (Downgrade)
Seeking Alpha · 2d ago
Crispr Therapeutics: Poised For A Major Turnaround
Seeking Alpha · 4d ago
Weekly Report: what happened at BLUE last week (1021-1025)?
Weekly Report · 4d ago
Largest borrow rate increases among liquid names
TipRanks · 10/23 12:45
Weekly Report: what happened at BLUE last week (1014-1018)?
Weekly Report · 10/21 09:11
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Seeking Alpha · 10/18 08:09
Weekly Report: what happened at BLUE last week (1007-1011)?
Weekly Report · 10/14 09:13
More
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). It is focused on pursuing curative gene therapies.

Webull offers bluebird bio Inc stock information, including NASDAQ: BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.